223 N Mathilda Ave
Tel: (800) 239-5230
23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80 percent of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases, conditions, and traits. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. 23andMe was named by Glassdoor as one of The Best Places to Work. CEO, Anne Wojcicki was also named one of Glassdoor’s top CEOs in 2019 and one of Comparably’s "Best CEOs for Women" in 2021. More information is available at www.23andMe.com.
Stock Symbol: ME
Stock Exchange: NASDAQ
Discover Your DNA Story With 23andMe!
176 articles with 23andMe
Many mergers took place in 2021. Here’s a look at some of the hottest life sciences SPAC merger announcements so far in 2021. Many mergers took place in 2021,
23andMe Holding Co. today announced the signing of a definitive merger agreement with Lemonaid Health, Inc.
Wanting to find out what is fueling the trend, BioSpace solicited the perspectives of a couple of executives who chose the SPAC route.
23andMe Holding Co., a leading consumer genetics and research company, announced that management will be participating in the Wells Fargo Virtual Healthcare Conference on Friday, September 10, 2021 at 8:20 a.m. Pacific Time / 11:20 a.m. Eastern Time.
23andMe Holding Co., a leading consumer genetics and research company, reported its financial results for the first quarter of its fiscal year 2022, which ended June 30, 2021.
The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industr...
23andMe Successfully Closes its Business Combination with VG Acquisition Corp.Combined Company to Trade on Nasdaq Under Ticker “ME” Commencing June 17
23andMe, Inc., a leading consumer genetics and research company, and VG Acquisition Corp., a special purpose acquisition company sponsored by Virgin Group, announced the completion of their previously announced business combination.
Michael J. Fox Foundation and 23andMe Share New Genetic Data from the Largest Cohort in Parkinson's Research
Collaboration with 23andMe enables robust sharing of de-identified genetic data with researchers worldwide through the Fox Insight Data Exploration Network (Fox DEN)
Symptom most commonly observed in women and younger respondents, less commonly in those of East Asian and African American ancestry
Virgin Group's VG Acquisition Corp. Announces Date of Shareholders Meeting in Connection with its Pending Business Combination with 23andMe
VG Acquisition Corp., a special purpose acquisition company sponsored by Virgin Group, announced that the date of its extraordinary general meeting of shareholders to vote on its proposed business combination with 23andMe, Inc., a leading consumer genetics and research company, will be June 10, 2021.
With 2020 holding a record number of biotech IPOs, this year is lining up to come close. Three more Bay Area life science companies are just about ready to hit the Nasdaq, adding to the growing list for 2021.
2/10/2021The cash just keeps coming for biopharma companies. Here’s a rundown of some of this week’s investment dollar recipients.
Billionaire Sir Richard Branson believes in healthcare. This week he put more of his money where his mouth is by using his SPAC to take consumer DNA testing company 23andMe public in a massive deal.
23andMe to Merge with Virgin Group's VG Acquisition Corp. to Become Publicly-Traded Company Set to Revolutionize Personalized Healthcare and Therapeutic Development through Human Genetics
- 23andMe is a leading consumer genetics and research company that offers a personalized health and wellness experience, and has built a premier genetic database to unlock insights leading to the rapid discovery of promising new targets for drug development - Transaction will provide the capital to fund additional investment in key growth initiatives across 23andMe's consumer health and therapeutics businesses
23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for Two Commonly Prescribed Medications
510(k) Clearance allows 23andMe to report interpretive drug information for medications prescribed for heart conditions and depression without the need for confirmatory testing
The layoffs are in departments across the company that aren’t central to its consumer testing and therapeutics business.
A competitor, Invitae Corporation, presented a poster at the American Society of Human Genetics (ASHG) annual meeting that essentially accuses 23andMe’s tests of completing missing a cancer-causing DNA variant in some ethnic groups.
23andMe Health + Ancestry Service Customer Survey Conducted by M/A/R/C Research: 76 Percent of Respondents Report Making a Positive Behavior Change After Getting 23andMe Results
Changes include diet, exercise, sleep and setting future health goals
23andMe and TrialSpark are announcing a joint clinical trial offering that combines the power of 23andMe's crowdsourced research platform and extensive database of consenting customers with TrialSpark's distributed site network and trial services.
March is National Women’s Month with March 8 specifically designated as International Women’s Day. Although this is not remotely a comprehensive list, BioSpace recognizes these 10 women (in no particular order) as being especially influential in the biopharma industry.